Your browser doesn't support javascript.
loading
Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease.
Locatelli, Francesco; Del Vecchio, Lucia; Esposito, Ciro; Gesualdo, Loreto; Grandaliano, Giuseppe; Ravera, Maura; Minutolo, Roberto.
Afiliación
  • Locatelli F; Department of Nephrology and Dialysis, Alessandro Manzoni Hospital, Lecco, Italy.
  • Del Vecchio L; Department of Nephrology and Dialysis, Sant'Anna Hospital, ASST Lariana, Como, Italy.
  • Esposito C; Nephrology and Dialysis Unit, IRCSS Maugeri, University of Pavia, Pavia, Italy.
  • Gesualdo L; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
  • Grandaliano G; Renal, Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari, Bari, Italy.
  • Ravera M; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Minutolo R; Nephrology, Dialysis and Transplantation Unit, Policlinico San Martino, Genoa, Italy.
J Nephrol ; 37(3): 753-767, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38705934
ABSTRACT
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new drugs developed for the treatment of anemia associated with chronic kidney disease (CKD). This class of drugs stimulates endogenous erythropoietin production and, at the same time, improves iron absorption and mobilization of iron stores (less evident with daprodustat, vadadustat and enarodustat). Several studies have been published in the last few years showing that these agents are not inferior to standard therapy in correcting anemia associated with CKD. The efficacy of HIF-PHIs is coupled with a safety profile comparable to that of standard erythropoiesis stimulating agent (ESA) treatment. However, studies with HIF-PHIs were not long enough to definitively exclude the impact of new drugs on adverse events, such as cancer, death and possibly cardiovascular events, that usually occur after a long follow-up period. Kidney Disease Improving Global Outcomes (KDIGO) recently reported the conclusions of the Controversies Conference on HIF-PHIs held in 2021. The goal of the present position paper endorsed by the Italian Society of Nephrology is to better adapt the conclusions of the latest KDIGO Conference on HIF-PHIs to the Italian context by reviewing the efficacy and safety of HIF-PHIs as well as their use in subpopulations of interest as emerged from more recent publications not discussed during the KDIGO Conference.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Prolina Dioxigenasas del Factor Inducible por Hipoxia / Anemia / Nefrología Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Nephrol Asunto de la revista: NEFROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Prolina Dioxigenasas del Factor Inducible por Hipoxia / Anemia / Nefrología Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Nephrol Asunto de la revista: NEFROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Italia